Differentiated Thyroid Cancer (DTC)

Thyroid cancer is the most common endocrine malignancy. Papillary, follicular (including Hürthle cell) and poorly differentiated types of thyroid cancer are classified as differentiated and account for the vast majority of all thyroid cancers.

Unmet Need

Many patients with DTC are successfully treated with radioactive iodine (RAI). However...

20-25% of cases are RAI-refractory in metastatic thyroid cancer.

Impact on Patients

RAI-refractory disease is more difficult to treat and is associated with a lower survival rate.

ONLY 10% of RAI-refractory patients survive 10 years after diagnosis, versus 60% of patients who do respond to RAI-therapy.

RAI-refractory patients have an average survival of 3 - 5 years.

Global Incidence

According to the World Health Organization, 298,102 people (68,179 men and 229,923 women) were diagnosed with thyroid cancer in 2012.

39,771 people died from thyroid cancer in 2012.

© 2016 Bayer Pharma AG. All rights reserved. BAYER® and the Bayer Cross® are registered trademarks of Bayer.